Literature DB >> 32630176

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model.

Fanny Lundmark1, Ayman Abouzayed1, Bogdan Mitran1,2, Sara S Rinne1, Zohreh Varasteh1,3, Mats Larhed4, Vladimir Tolmachev5,6, Ulrika Rosenström1, Anna Orlova1,4,6.   

Abstract

Prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR) are promising targets for molecular imaging of prostate cancer (PCa) lesions. Due to the heterogenic overexpression of PSMA and GRPR in PCa, a heterodimeric radiotracer with the ability to bind to both targets could be beneficial. Recently, our group reported the novel heterodimer BQ7800 consisting of a urea-based PSMA inhibitor, the peptide-based GRPR antagonist RM26 and NOTA chelator. The study reported herein, aimed to improve the affinity of BQ7800 towards PSMA by changing the composition of the two linkers connecting the PSMA- and GRPR-targeting motifs. Three novel heterodimeric analogues were synthesized by incorporation of phenylalanine in the functional linker of the PSMA-binding motif and/or shortening the PEG-linker coupled to RM26. The heterodimers were labeled with indium-111 and evaluated in vitro. In the competitive binding assay, BQ7812, featuring phenylalanine and shorter PEG-linker, demonstrated a nine-fold improved affinity towards PSMA. In the in vivo biodistribution study of [111In]In-BQ7812 in PC3-pip tumor-bearing mice (PSMA and GRPR positive), the activity uptake was two-fold higher in the tumor and three-fold higher in kidneys than for [111In]In-BQ7800. Herein, we showed that the affinity of a bispecific PSMA/GRPR heterodimer towards PSMA could be improved by linker modification.

Entities:  

Keywords:  GRPR; PSMA; SPPS; heterodimer; molecular imaging; prostate cancer

Year:  2020        PMID: 32630176     DOI: 10.3390/pharmaceutics12070614

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  2 in total

1.  Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands.

Authors:  Fanny Lundmark; Gustav Olanders; Sara Sophie Rinne; Ayman Abouzayed; Anna Orlova; Ulrika Rosenström
Journal:  Pharmaceutics       Date:  2022-05-20       Impact factor: 6.525

Review 2.  Radiolabeled PSMA Inhibitors.

Authors:  Oliver C Neels; Klaus Kopka; Christos Liolios; Ali Afshar-Oromieh
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.